ZYBERNO
Stock Report
Updated Sep 1, 2026

BioLineRx Ltd. (BLRX)

Healthcare • NASDAQ

$2.72

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
19.0/100
POOR BUSINESS
BioLineRx Ltd. (BLRX) scores 19/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-38.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BioLineRx Ltd. (BLRX) stock report — Zyberno Score 19/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.72
Market Cap:$38.74M

Valuation Multiples (3)

P/B Ratio:1.66x
P/S Ratio:32.83x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$35.49M

Price Action & Momentum (3)

Momentum Percentile:16 / 100
% of 52-Week High:113.3%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:6.5%
Fundamental Growth Rate (g):-2.5%

Margin Analysis (1)

Ebitda Margin:-827.5%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.95x
Quick Ratio:1.78x
Cash Ratio:0.27x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-2.52x
Times Interest Earned:-2.52

Capital Structure (4)

Working Capital:11,558,000.00
Cash And Cash Equivalents:3,250,000.00
Long Term Debt:$0.00
Net Debt:-$3.25M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$1.18M
Cost Of Revenue Ttm:$230.00K

Profitability Breakdown (2)

$950.00K-$10.29M

Bottom Line Performance (3)

-$2.03M
Income Before Tax:$0.00
Ebitda Ttm:-9,764,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:$0.00
Interest Expense:4,077,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:-827.5%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$40.91M
Current Assets:$23.68M
Ppe Net:160,000.00
Goodwill:0.00
Intangible Assets:$16.37M

Liability Structure (4)

Total Liabilities:17,560,000.00
Current Liabilities:12,123,000.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$23.35M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:2,148,000.00
Accounts Payable:3,493,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$8.07M-$8.10M

Investment Activities (1)

Investing Cash Flow:-$8.55M

Financing Activities (3)

Financing Cash Flow:$8.88M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.14

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.08
Operating Cash Flow Per Share:-$0.57

Book Value & Capital (2)

Book Value Per Share:$1.64
Cash Per Share:0.23

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.03x
Working Capital Turnover Ttm:0.10x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:0.11x
Days Inventory Outstanding Ttm:3,408.78

Payables & Cash Cycle (2)

Days Payable Outstanding:5,543.24
Cash Conversion Cycle:-3,133.46
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:6.5%
Fundamental Growth Rate (g):-2.5%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:BLRX
Company Name:BioLineRx Ltd.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:14.24M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 14:07:46 UTC
Data Timestamp:2026-08-21T11:08:02.601774
Scroll to Top